Abstract | OBJECTIVE: DESIGN: Double-blind, prospectively randomised, three-way crossover study of mebeverine, mefenamic acid and placebo during three consecutive menstrual cycles. SETTING: University health centres in the UK. PATIENTS: Sixty-four females suffering from primary dysmenorrhoea who experienced pain during every menstrual cycle. INTERVENTION: MEASUREMENTS AND RESULTS: Details of pain severity, nausea, abdominal bloating and disruption to daily activities were recorded by means of clinician assessments and patient diaries. Patients indicated their treatment preference after three cycles. Mebeverine and mefenamic acid were superior to placebo in reducing pain severity (p less than 0.01 and p less than 0.02 respectively), and mefenamic acid reduced the level of disruption to normal activities (p less than 0.01). The number of concurrent effects reported was five during treatment with mefenamic acid and one each during treatment with placebo and mebeverine. CONCLUSIONS:
|
Authors | A F Langrick, A D Gunn, H Livesey, A M Whitehead |
Journal | The British journal of clinical practice
(Br J Clin Pract)
Vol. 43
Issue 9
Pg. 317-21
(Sep 1989)
ISSN: 0007-0947 [Print] England |
PMID | 2620043
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Phenethylamines
- Mefenamic Acid
- mebeverine
|
Topics |
- Adolescent
- Adult
- Double-Blind Method
- Dysmenorrhea
(drug therapy)
- Female
- Humans
- Mefenamic Acid
(therapeutic use)
- Phenethylamines
(therapeutic use)
- Prospective Studies
- Random Allocation
|